Bevacizumab Associated Renal Adverse Events Signal Better Prognosis in Ovarian Cancer
Kidney360 · 2026
DOI: 10.34067/kid.0000001137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, 2026. Verfasst von Cristina Riaza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain. Hauptthemen laut MEDLINE: Bevacizumab, Ovarian Neoplasms, Proteinuria, Hypertension. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Bevacizumab, a monoclonal antibody targeting VEGF-A, is a cornerstone in ovarian cancer. Bevacizumab is associated with renal adverse events, including hypertension, proteinuria, and acute kidney injury. The incidence, risk factors, and prognostic impact of these renal events remain poorly defined. This study aimed to determine the incidence, risk factors, and association with mortality of renal events in patients with ovarian cancer treated with bevacizumab.
Methods
We conducted a retrospective single-center study including 147 patients with ovarian cancer treated with bevacizumab between 2011 and 2023. Renal events were defined as new-onset or worsening hypertension (grade ≥2), proteinuria (grade ≥2), and/or acute kidney injury, as per CTCAE v5.0 and KDIGO guidelines.
Results
Over a median follow-up of 52 months, 34.7% of patients developed a renal event, most commonly hypertension (27.9%), followed by proteinuria (6.8%) and acute kidney injury (6.8%). Only a history of hypertension was identified as an independent risk factor for renal event (p=0.0078). Importantly, patients with renal events had significantly longer survival compared to those who did not (p=0.0243). In the multivariate analysis, the occurrence of a renal event emerged as a protective factor against mortality.
Conclusions
In conclusion, renal events occurred in 34.7% of bevacizumab -treated patients. Hypertension was a risk factor for renal event, but renal events appeared to be a protective factor against mortality. Rather than signaling harm, their presence may reflect effective VEGF pathway inhibition and greater antitumor response. Routine monitoring and early nephrological management of hypertension, proteinuria, and acute kidney injury are essential to optimize treatment continuity and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain.
- Biomedical Research Institute of San Carlos Clinical University Hospital, Madrid, Spain.
- Department of Medical Oncology, School of Medicine, San Carlos Clinical University Hospital, EURACAN Referral Centre, UCM, IdissC, Madrid, Spain.
- Department of Medicine, Complutense University, Madrid, Spain.
ORCID-Profile: Cristina Riaza, Marta Álvarez-Nadal, Antonio Casado, Gloria Marquina, Marta Calvo, Antolina Rodríguez-Moreno, Ana I Sánchez-Fructuoso
Zitieren
APA
Riaza, C., Álvarez-Nadal, M., Casado, A., Marquina, G., Calvo, M., Rodríguez-Moreno, A., Rivero, M., Sánchez-Fructuoso, A. I., & García-Carro, C. (2026). Bevacizumab Associated Renal Adverse Events Signal Better Prognosis in Ovarian Cancer. Kidney360. https://doi.org/10.34067/kid.0000001137
Vancouver
Riaza C, Álvarez-Nadal M, Casado A, Marquina G, Calvo M, Rodríguez-Moreno A, et al. Bevacizumab Associated Renal Adverse Events Signal Better Prognosis in Ovarian Cancer. Kidney360. 2026. doi:10.34067/kid.0000001137
BibTeX
@article{Riaza2026,
author = {Riaza, Cristina and Álvarez-Nadal, Marta and Casado, Antonio and Marquina, Gloria and Calvo, Marta and Rodríguez-Moreno, Antolina and Rivero, Marta and Sánchez-Fructuoso, Ana I and García-Carro, Clara},
title = {Bevacizumab Associated Renal Adverse Events Signal Better Prognosis in Ovarian Cancer},
journal = {Kidney360},
year = {2026},
doi = {10.34067/kid.0000001137}
}
EUVIMED